Compound comparison
Retatrutide vs Tirzepatide
This page sets Retatrutide and Tirzepatide side by side using the data recorded on Peptide Science Daily: drug class, mechanism of action, regulatory status by region, the evidence grade assigned here, and the number of clinical trials tracked. It is a neutral, factual comparison and does not rank either compound or recommend one over the other.
Side-by-side comparison
| Attribute | Retatrutide | Tirzepatide |
|---|---|---|
| Class | Triple agonist of the GIP, GLP-1, and glucagon receptors (investigational incretin/metabolic peptide) | Dual agonist of the GIP and GLP-1 receptors (incretin-based metabolic peptide) |
| Mechanism | In plain terms, retatrutide mimics several natural gut and pancreatic hormones at once to reduce appetite and food intake while affecting how the body handles glucose and energy. | In plain terms, tirzepatide imitates two natural gut hormones that lower blood sugar and reduce appetite. |
| United States (FDA) | Investigational; not approved. Phase 3 TRIUMPH program ongoing, with a first positive topline readout (TRIUMPH-4) reported in December 2025. | Approved. Mounjaro for type 2 diabetes (May 2022); Zepbound for chronic weight management (November 2023) and for moderate-to-severe obstructive sleep apnea in adults with obesity (December 2024). |
| European Union (EMA) | Not authorized; investigational, no marketing authorization. | Authorized (Mounjaro) for type 2 diabetes and weight management (marketing authorization granted September 2022). |
| Australia (TGA) | Not entered on the Australian Register of Therapeutic Goods (ARTG); investigational only and not approved for supply. | Registered on the ARTG (Mounjaro) for type 2 diabetes and for weight management, available on prescription. |
| WADA | Not listed on the WADA Prohibited List. As an investigational incretin-class agent it is not a banned substance; the closely related approved GLP-1 agonists are on WADA's monitoring program rather than prohibited. | Not prohibited. Added to the WADA 2026 Monitoring Program, with markers tracked in- and out-of-competition to detect patterns of misuse; not a banned substance. |
| Evidence grade | B | A |
| Tracked clinical trials | 34 | 252 |
| Full profile | Retatrutide profile | Tirzepatide profile |
Common questions
- What is the difference between Retatrutide and Tirzepatide?
- Retatrutide is classified as: Triple agonist of the GIP, GLP-1, and glucagon receptors (investigational incretin/metabolic peptide). Tirzepatide is classified as: Dual agonist of the GIP and GLP-1 receptors (incretin-based metabolic peptide). Retatrutide is investigational and is not an approved medicine. Tirzepatide is approved for one or more medical uses in at least one major jurisdiction.
- Is Retatrutide or Tirzepatide approved?
- Retatrutide is investigational and is not an approved medicine. Tirzepatide is approved for one or more medical uses in at least one major jurisdiction. Regulatory status by region is set out in the table above.
- How much clinical trial evidence is tracked for Retatrutide and Tirzepatide?
- Peptide Science Daily tracks 34 registered clinical trials for Retatrutide (evidence grade B) and 252 for Tirzepatide (evidence grade A).